HCA 保健处的库存目标在收入丰厚和2026年前景乐观的基础上提高到573美元,尽管收入略微不足。 HCA Healthcare's stock target raised to $573 on strong earnings and upbeat 2026 outlook, despite slight revenue miss.

莱林克合伙人将HCA医疗保健的股价目标提高到573美元,反映出第四季度每股8.01美元的强收益,超出预期,并更新了2026财年每股收益2910美元和3150美元的预测. HCA Healthcare's stock price target was raised to $573 by Leerink Partners, reflecting strong Q4 earnings of $8.01 per share—surpassing expectations—and updated FY2026 guidance of $29.10–$31.50 EPS. 收入逐年增加6.7%,达到19.51亿美元,略微缺少估计数。 Revenue rose 6.7% year-over-year to $19.51 billion, slightly missing estimates. 包括高盛、杰弗利和德意志银行在内的多家公司也增加了目标,理由是对医管局的门诊扩张、收购和医院在卫生等级最高名单上的承认有信心。 Multiple firms, including Goldman Sachs, Jefferies, and Deutsche Bank, also increased targets, citing confidence in HCA’s outpatient expansion, acquisitions, and hospital recognitions on Healthgrades’ top lists. 股票交易额近482美元,市场上限为1 100亿美元,但监管和偿还变化的风险依然存在。 The stock traded near $482 with a market cap of $110 billion, though risks from regulatory and reimbursement changes remain.